Related Experiment Video
Updated: Jun 4, 2026
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
4-Methlycatechol prevents NGF/p75(NTR)-mediated apoptosis via NGF/TrkA system in pancreatic β cells
Selda Gezginci-Oktayoglu1, Sehnaz Bolkent
1Department of Biology, Faculty of Science, Istanbul University, 34134 Vezneciler, Istanbul, Turkey. selgez@istanbul.edu.tr
Abstract:
In this study, it was aimed to investigate whether 4-methylcatechol (4-MC) could serve as an autocrine antiapoptotic agent by increasing nerve growth factor (NGF) in β cells of hyperglycemic rats. Rats were divided into four groups: the first group was given citrate buffer and saline, the second group was administered 4-MC, the third group received streptozotocin (STZ), and the fourth group was given both 4-MC and STZ. 4-MC (10 μg/kg) was administered by daily intraperitoneal injection for 10 days before the animals were rendered hyperglycemic by administration of STZ (75 mg/kg). With 4-MC pretreatment on hyperglycemic rats the following results were noted: (i) Increase in plasma glucose, β cell apoptosis and caspase-8 activation was prevented. (ii) Reduction of NGF+ and tyrosine receptor kinase A (TrkA)+ β cell number was blocked. (iii) p75 neurotrophin receptor (p75(NTR))+ β cell number was increased. These data suggest that 4-MC might exert its antiapoptotic actions through NGF/TrkA system which may block NGF/p75(NTR) activation in pancreatic β cells of hyperglycemic rats.
Insights
4-methylcatechol (4-MC) prevents beta cell apoptosis in hyperglycemic rats by increasing nerve growth factor (NGF). This suggests 4-MC may protect pancreatic beta cells via the NGF/TrkA pathway, blocking NGF/p75(NTR) activation.
Area of Science:
- Endocrinology
- Cell Biology
- Neuroscience
Background:
- Hyperglycemia can induce pancreatic beta cell apoptosis, contributing to diabetes.
- Nerve growth factor (NGF) plays a role in beta cell survival and function.
- The interplay between NGF signaling pathways (NGF/TrkA and NGF/p75(NTR)) in beta cells under hyperglycemic conditions requires further elucidation.
Purpose of the Study:
- To investigate the potential of 4-methylcatechol (4-MC) as an autocrine antiapoptotic agent in pancreatic beta cells.
- To determine if 4-MC increases nerve growth factor (NGF) levels in beta cells of hyperglycemic rats.
- To explore the involvement of NGF/TrkA and NGF/p75(NTR) signaling pathways in the protective effects of 4-MC.
Main Methods:
- Rats were divided into four groups: control, 4-MC treated, streptozotocin (STZ) induced hyperglycemia, and 4-MC + STZ treated.
- 4-MC was administered intraperitoneally for 10 days prior to STZ injection to induce hyperglycemia.
- Plasma glucose levels, beta cell apoptosis, caspase-8 activation, and the expression of NGF, TrkA, and p75(NTR) in beta cells were assessed.
Main Results:
- 4-MC pretreatment prevented the STZ-induced increase in plasma glucose, beta cell apoptosis, and caspase-8 activation.
- The reduction in NGF-positive (NGF+) and tyrosine receptor kinase A (TrkA)+ beta cell numbers was blocked by 4-MC.
- 4-MC administration led to an increase in p75 neurotrophin receptor (p75(NTR))+ beta cell numbers.
Conclusions:
- 4-methylcatechol (4-MC) exhibits antiapoptotic effects in pancreatic beta cells of hyperglycemic rats.
- These protective effects appear to be mediated through the NGF/TrkA signaling pathway.
- 4-MC may exert its protective action by inhibiting NGF/p75(NTR) activation in beta cells during hyperglycemia.
